Drug Approval | June 17, 2025
USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Sun Pharma gets 8 observations from USFDA for Halol facility
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Ranks among the top 15% companies globally
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
